Table 3
Further investigations at age 27 years
| Lymphocyte subsets | Cells/μl |
|---|---|
| Total CD19+ B cells (normal, 200–400) | 32 |
| Total CD3+ Tcells (normal, 1100–1700) | 1562 |
| CD8+ T cells (normal, 500–900) | 1008 |
| CD4+ T cells (normal, 700–1100) | 1103 |
| CD16+CD56+ NK cells (normal, 200–400) | 48 |
| Lymphocyte proliferation assays | |||||
|---|---|---|---|---|---|
| Activator | Patient (cpm) | Control (cpm) | Patient SI | Control SI | |
| Values in bold are lower than normal. | |||||
| cpm, counts/minute; IL-2, interleukin 2; NK, natural killer; PHA, phytohaemagglutinin; PMA, phorbol myristyl acetate; SI, stimulation index. | |||||
| None | 93 | 395 | |||
| PHA | 15 835 | 133 751 | 170 | 339 | |
| Concanavalin A | 18 852 | 111 078 | 203 | 281 | |
| PMA | 13 813 | 23 845 | 149 | 60 | |
| PMA + Ionophore | 29 060 | 63 942 | 312 | 162 | |
| Anti CD3 + IL-2 | 82 142 | 52 922 | 883 | 134 | |
| NK cell function assay | |||||
| Expressed as percentage of K562 cells killed by mononuclear cell population | |||||
| Patient | 10.1% | ||||
| Normal range | 7.5–40% | ||||
